Intec Pharma LTD stock analysis
Company: Intec Pharma LTD
Quote:NASDAQ: NTEC
Buy Target : $6.90 (original hold) $7.25 Second entry
Sell Target: $30 EOY [$12 after AP-CD Approval],[THC/CBD Phase 2- $30 on speculation]
Description: Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. It's Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Short Interest:
Short Percent of Float ?%
Short % Increase / Decrease 21 %
Tapes last week: 1/5 Very bearish no major buying and large sell blocks during the week
Please follow us on our Facebook and Twitter to get the analysis on your social media. Subscribe to our newsletter to get our analysis directly to your mail
Facebook - SFYBUofficial
Twitter - SFYBUofficial
Quote:NASDAQ: NTEC
Buy Target : $6.90 (original hold) $7.25 Second entry
Sell Target: $30 EOY [$12 after AP-CD Approval],[THC/CBD Phase 2- $30 on speculation]
Description: Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. It's Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Short Interest:
Short Percent of Float ?%
Short % Increase / Decrease 21 %
Tapes last week: 1/5 Very bearish no major buying and large sell blocks during the week
Please follow us on our Facebook and Twitter to get the analysis on your social media. Subscribe to our newsletter to get our analysis directly to your mail
Facebook - SFYBUofficial
Twitter - SFYBUofficial
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.